AF
NBIX icon

Avanza Fonder’s Neurocrine Biosciences NBIX Stock Holding History

Avanza Fonder’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,890
Closed -$552K – 503
2025
Q4 		$552K Buy
3,890
+149
+4% +$21.6K 0.01% 402
2025
Q3 		$525K Buy
3,741
+474
+15% +$64.2K 0.01% 368
2025
Q2 		$411K Sell
3,267
-9,207
-74% -$1.06M 0.01% 372
2025
Q1 		$1.35M Sell
12,474
-744
-6% -$94.3K 0.04% 311
2024
Q4 		$1.8M Buy
+13,218
New +$1.63M 0.05% 267

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avanza Fonder's NBIX Position: Q1 2026 in Review

Avanza Fonder sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 3,890 shares — an estimated $552K sold.

Avanza Fonder first reported a position in NBIX in Q4 2024 and held it in 5 quarters. The position peaked at $1.8M in Q4 2024. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Avanza Fonder reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Avanza Fonder sold 3,890 Neurocrine Biosciences shares in Q1 2026, an estimated $552K.
  • Avanza Fonder first reported a position in Neurocrine Biosciences in Q4 2024 and held it in 5 quarters.
  • Avanza Fonder's Neurocrine Biosciences position peaked at $1.8M in Q4 2024.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Avanza Fonder's 13F filing for Q1 2026, filed 15 Apr 2026.